RepTrak's New and Improved Multi-Country Dashboard
RepTrak's new and improved Multi-Country Dashboard delivers the flexibility and insights you need to seamlessly track your reputation across regions.
Reputation Intelligence for the Pharmaceutical Industry
RepTrak for Pharma
Leverage data-driven insights to monitor, measure, and manage your reputation in the Pharmaceutical industry.
Balancing Innovation with Public Trust.
While innovation drives progress, public skepticism around drug pricing, transparency, and ethics can erode trust. Negative perceptions not only damage stakeholder relationships but also impact market value. In this high-stakes environment, maintaining your brand's reputation is essential to long-term success.
Your Strategic Partner
RepTrak equips Pharma companies with the tools necessary to navigate complex reputational challenges. With continuous insights into public sentiment, media impact, and regulatory perceptions, RepTrak empowers teams to make data-driven decisions. Our team of experts partner with clients to manage risks, enhance trust, and stay ahead in an evolving industry.
Insights & Recommendations
Recommendations from experts who understand the nuances of the Pharma industry across global markets.
Proven Methodology
Scientifically validated approach, fine-tuned for Pharma, providing insights you can act on with confidence.
Historical Database
Leverage millions of global data points from over 20 years and learn from leaders who’ve transformed their reputation.
Built for Data-Driven Communication Teams
Insights and Recommendations from Industry Experts
Stakeholder Analysis
Gain insights into the perceptions and expectations of patients, regulators, healthcare professionals, and other key stakeholders.
Global & Local Pharma Insights
2024 Pharma Report
The 2024 Pharma Report offers a comprehensive view of the Pharmaceutical industry's reputation landscape, highlighting key trends and challenges across global markets. As public expectations continue to rise in the post-pandemic environment, Pharma companies are confronted with increased regulations, demands for quick innovations, and shaky relationships with critical stakeholders.
Fill out the form to learn more about what's driving the industry's reputation recovery — and where improvement is still needed.
Previous reports can be found here:
Fill out the form
Download the 2024 report here
Loading...
STAY UPDATED
See the latest reputation insights
Q3 Data Dose: Insight to Action Quick-Slides
Our latest quick-slides showcase the top 4 insights from our Q3 Current Events Data study, paired with actionable strategies to strengthen stakeholder favor.
Q3 Data Dose: Sustainability Stakes One-Pager
Our latest data dose is here to help you understand exactly where stakeholders’ priorities lie so you can start planning your 2025 reputation strategy with precise actions.
Ethics in Action: Quick-Slides
Our latest quick-slides offer 5 ways to leverage ethical conduct for long-term business success.
5 Ways to Leverage Ethical Conduct for Business Success
This blog explores how organizations can leverage ethical behavior as a strategic asset to elevate their reputation, earn stakeholder trust, and drive meaningful business outcomes.
The RepTrak Company is Acquired by Periscope Equity
The RepTrak Company announces a transformative shift in majority ownership following its acquisition by Periscope Equity.
2024 Financial Services Report Quick-Slides: Profits & Purpose
Our latest set of quick-slides provides Financial Services companies with 3 actionable Citizenship tips to help increase stakeholder favor and enhance corporate reputation.
2024 Financial Services Report One-Pager: Trust vs. Reputation
Our latest one-pager breaks down the differences between Trust and Reputation, and why it is important for Financial Services companies to measure both.
2024 Financial Services Report
Our latest report explores how stakeholder confidence in financial institutions is being restored.
RepTrak Launches “RepTrak for Industry”
Groundbreaking industry-specific reputation insights and advanced stakeholder analysis empowers businesses to navigate challenges and build trust globally.
RepTrak's New and Improved Multi-Country Dashboard
RepTrak's new and improved Multi-Country Dashboard delivers the flexibility and insights you need to seamlessly track your reputation across regions.
Q3 Data Dose: Insight to Action Quick-Slides
Our latest quick-slides showcase the top 4 insights from our Q3 Current Events Data study, paired with actionable strategies to strengthen stakeholder favor.
Q3 Data Dose: Sustainability Stakes One-Pager
Our latest data dose is here to help you understand exactly where stakeholders’ priorities lie so you can start planning your 2025 reputation strategy with precise actions.
Ethics in Action: Quick-Slides
Our latest quick-slides offer 5 ways to leverage ethical conduct for long-term business success.
5 Ways to Leverage Ethical Conduct for Business Success
This blog explores how organizations can leverage ethical behavior as a strategic asset to elevate their reputation, earn stakeholder trust, and drive meaningful business outcomes.
The RepTrak Company is Acquired by Periscope Equity
The RepTrak Company announces a transformative shift in majority ownership following its acquisition by Periscope Equity.
2024 Financial Services Report Quick-Slides: Profits & Purpose
Our latest set of quick-slides provides Financial Services companies with 3 actionable Citizenship tips to help increase stakeholder favor and enhance corporate reputation.
2024 Financial Services Report One-Pager: Trust vs. Reputation
Our latest one-pager breaks down the differences between Trust and Reputation, and why it is important for Financial Services companies to measure both.
2024 Financial Services Report
Our latest report explores how stakeholder confidence in financial institutions is being restored.
RepTrak Launches “RepTrak for Industry”
Groundbreaking industry-specific reputation insights and advanced stakeholder analysis empowers businesses to navigate challenges and build trust globally.